• Aker BioMarine’s annual report said the company delivered revenue growth and improved profitability, citing stronger performance in Human Health Ingredients and cost management.
• Human Health Ingredients was described as the main growth driver, supported by new supply agreements for Superba Krill Oil and a Sports Research krill oil launch in the U.S. that reached Costco shelves.
• Consumer Health Products was reported as stable versus the prior year, with shifting demand patterns and a cautious retail environment.
• R&D updates included the initiation of a human clinical trial for Lysoveta and continued development of the algae-based omega-3 platform Revervia.
• The report said the company initiated a process to explore strategic alternatives for the Human Health Ingredients business, aiming to progress toward a potential transaction in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aker BioMarine ASA published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.